Chengdu Suncadia Medicine Co., Ltd.
Clinical trials sponsored by Chengdu Suncadia Medicine Co., Ltd., explained in plain language.
-
New hope for PNH patients who still struggle with anemia despite current treatments
Disease control CompletedThis Phase 3 trial tested whether HRS-5965 capsules could help patients with paroxysmal nocturnal hemoglobinuria (PNH) who continue to have anemia despite already receiving standard C5 inhibitor treatments like eulizumab. The study involved 39 adults who took the capsules for 24 …
Phase: PHASE3 • Sponsor: Chengdu Suncadia Medicine Co., Ltd. • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New oral treatment challenges standard therapy for rare blood disorder
Disease control CompletedThis study tested whether HRS-5965 capsules work as well as the standard treatment (eculizumab) for paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder. The 24-week trial involved 76 patients who had not previously received complement inhibitor therapy. Researchers m…
Phase: PHASE3 • Sponsor: Chengdu Suncadia Medicine Co., Ltd. • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
First human test of new drug explores safety in people with liver problems
Knowledge-focused CompletedThis early-stage study tested how a single dose of the experimental drug HRS-5965 behaves in people with and without liver problems. It involved 24 adults with kidney disease to see if liver function changes how the drug is processed in the body and to check for safety. The goal …
Phase: PHASE1 • Sponsor: Chengdu Suncadia Medicine Co., Ltd. • Aim: Knowledge-focused
Last updated Apr 02, 2026 02:11 UTC
-
Scientists test different pills to find best version for future treatments
Knowledge-focused CompletedThis early-stage study aimed to see if the body absorbs a new drug, HRS-5965, differently when it's in a capsule versus a tablet. It involved 16 healthy male volunteers to compare the two pill forms. The goal is to gather basic information to help design future studies for treati…
Phase: PHASE1 • Sponsor: Chengdu Suncadia Medicine Co., Ltd. • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:32 UTC